Target discovery from data mining approaches

Y Yang, SJ Adelstein, AI Kassis - Drug discovery today, 2012 - Elsevier
Data mining of available biomedical data and information has greatly boosted target
discovery in the 'omics' era. Target discovery is the key step in the biomarker and drug …

The epigenetic promise for prostate cancer diagnosis

L Van Neste, JG Herman, G Otto, JW Bigley… - The …, 2012 - Wiley Online Library
BACKGROUND Prostate cancer is the most common cancer diagnosis in men and a leading
cause of death. Improvements in disease management would have a significant impact and …

IGFBP3 impedes aggressive growth of pediatric liver cancer and is epigenetically silenced in vascular invasive and metastatic tumors

I Regel, M Eichenmüller, S Joppien, J Liebl, B Häberle… - Molecular cancer, 2012 - Springer
Background Hepatoblastoma (HB) is an embryonal liver neoplasm of early childhood with a
poor prognosis for patients with distant metastases and vascular invasion. We and others …

MicroRNAs as putative mediators of treatment response in prostate cancer

F O'kelly, L Marignol, A Meunier, TH Lynch… - Nature Reviews …, 2012 - nature.com
MicroRNAs (miRNAs) are an abundant class of noncoding RNAs that function to regulate
post-transcriptional gene expression, predominantly by translational repression. In addition …

Gemcitabine reactivates epigenetically silenced genes and functions as a DNA methyltransferase inhibitor

SG Gray, AM Baird, F O'Kelly… - International …, 2012 - spandidos-publications.com
Gemcitabine is indicated in combination with cisplatin as first-line therapy for solid tumours
including non-small cell lung cancer (NSCLC), bladder cancer and mesothelioma …

IGFBP7 Promoter Methylation and Gene Expression Analysis in Prostate Cancer

L Sullivan, TM Murphy, C Barrett, B Loftus… - The Journal of …, 2012 - auajournals.org
Purpose: IGFBP7 belongs to a family of insulin-like growth factor-1 regulatory binding
proteins. IGFBP7 hypermethylation is associated with its down-regulation in various …

Docetaxel maintains its cytotoxic activity under hypoxic conditions in prostate cancer cells

JC Forde, AS Perry, K Brennan, LM Martin… - … Oncology: Seminars and …, 2012 - Elsevier
OBJECTIVE:: The efficacy of docetaxel has recently been shown to be increased under
hypoxic conditions through the down-regulation of hypoxia-inducible-factor 1α (HIF1A) …

[图书][B] Investigation of novel progression-related methylation events and HOXD genes in prostate cancer

K Kron - 2012 - search.proquest.com
Aberrant DNA methylation in gene promoters causes gene silencing and is a common event
in prostate cancer development and progression. While commonly identified methylated …